Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen

Anil Vangala, Vincent W. Bramwell, Sarah McNeil, Dennis Christensen, Else Marie Agger, Yvonne Perrie

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

There is a clinical need for a more effective vaccine against hepatitis B, and in particular vaccines that may be suitable for therapeutic administration. This study assesses the potential of cationic surfactant vesicle based formulations using two agents; the cationic amine containing [N-(N',N'-dimethylaminoethane)-carbamoyl] cholesterol (DC-Chol) or dimethyl dioctadecylammonium bromide (DDA) with hepatitis B surface antigen (HBsAg). Synthetic mycobacterial cord factor, trehalose 6,6'-dibehenate (TDB) has been used as an adjuvant and the addition of 1-monopalmitoyl glycerol (C16:0) (MP) and cholesterol (Chol) to DDA-TDB is assessed for its potential to facilitate formation of dehydration-rehydration vesicles (DRV) at room temperature, and the effect of this on immune responses. A DRV formulation is directly compared to an adsorbed formulation of the same composition and preparation protocol (MP:dioleoyl phosphoethanolamine (DOPE):Chol:DC-Chol) and the direct substitution of MP with phosphatidylcholine (PC) is also compared in DRV antigen-entrapped formulations. MP and Chol were shown to facilitate the use of DDA-TDB in DRV formulations prepared at room temperature, whilst there was marginal alteration of immunogenicity (a reduction in HBsAg-specific IL-2). The HBsAg adsorbed DRV formulation was not significantly different from the HBsAg entrapped DRV formulation. Overall, DDA formulations incorporating TDB showed markedly increased antigen specific splenocyte proliferation and elicited cytokine production concomitant with a strong T cell driven response, delineating formulations that may be useful for further evaluation of their clinical potential.

LanguageEnglish
Pages102-110
Number of pages9
JournalJournal of Controlled Release
Volume119
Issue number1
DOIs
Publication statusPublished - 14 May 2007

Fingerprint

Fluid Therapy
Hepatitis B Surface Antigens
Dehydration
Bromides
Antigens
Cholesterol
Cord Factors
Hepatitis B Vaccines
Temperature
Phosphatidylcholines
Surface-Active Agents
Glycerol
Amines
Interleukin-2
Vaccines
Cytokines
T-Lymphocytes
trehalose 6,6'-dibehenate

Keywords

  • cultured cells
  • drug delivery systems
  • hepatitis B surface antigens
  • liposomes
  • mice
  • inbred BALB C mice
  • spleen

Cite this

Vangala, Anil ; Bramwell, Vincent W. ; McNeil, Sarah ; Christensen, Dennis ; Agger, Else Marie ; Perrie, Yvonne. / Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen. In: Journal of Controlled Release. 2007 ; Vol. 119, No. 1. pp. 102-110.
@article{93e3bbe1ab004f3e874d10ea06fddf2c,
title = "Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen",
abstract = "There is a clinical need for a more effective vaccine against hepatitis B, and in particular vaccines that may be suitable for therapeutic administration. This study assesses the potential of cationic surfactant vesicle based formulations using two agents; the cationic amine containing [N-(N',N'-dimethylaminoethane)-carbamoyl] cholesterol (DC-Chol) or dimethyl dioctadecylammonium bromide (DDA) with hepatitis B surface antigen (HBsAg). Synthetic mycobacterial cord factor, trehalose 6,6'-dibehenate (TDB) has been used as an adjuvant and the addition of 1-monopalmitoyl glycerol (C16:0) (MP) and cholesterol (Chol) to DDA-TDB is assessed for its potential to facilitate formation of dehydration-rehydration vesicles (DRV) at room temperature, and the effect of this on immune responses. A DRV formulation is directly compared to an adsorbed formulation of the same composition and preparation protocol (MP:dioleoyl phosphoethanolamine (DOPE):Chol:DC-Chol) and the direct substitution of MP with phosphatidylcholine (PC) is also compared in DRV antigen-entrapped formulations. MP and Chol were shown to facilitate the use of DDA-TDB in DRV formulations prepared at room temperature, whilst there was marginal alteration of immunogenicity (a reduction in HBsAg-specific IL-2). The HBsAg adsorbed DRV formulation was not significantly different from the HBsAg entrapped DRV formulation. Overall, DDA formulations incorporating TDB showed markedly increased antigen specific splenocyte proliferation and elicited cytokine production concomitant with a strong T cell driven response, delineating formulations that may be useful for further evaluation of their clinical potential.",
keywords = "cultured cells, drug delivery systems, hepatitis B surface antigens, liposomes, mice, inbred BALB C mice, spleen",
author = "Anil Vangala and Bramwell, {Vincent W.} and Sarah McNeil and Dennis Christensen and Agger, {Else Marie} and Yvonne Perrie",
year = "2007",
month = "5",
day = "14",
doi = "10.1016/j.jconrel.2007.01.010",
language = "English",
volume = "119",
pages = "102--110",
journal = "Journal of Controlled Release",
issn = "0168-3659",
number = "1",

}

Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen. / Vangala, Anil; Bramwell, Vincent W.; McNeil, Sarah; Christensen, Dennis; Agger, Else Marie; Perrie, Yvonne.

In: Journal of Controlled Release, Vol. 119, No. 1, 14.05.2007, p. 102-110.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen

AU - Vangala, Anil

AU - Bramwell, Vincent W.

AU - McNeil, Sarah

AU - Christensen, Dennis

AU - Agger, Else Marie

AU - Perrie, Yvonne

PY - 2007/5/14

Y1 - 2007/5/14

N2 - There is a clinical need for a more effective vaccine against hepatitis B, and in particular vaccines that may be suitable for therapeutic administration. This study assesses the potential of cationic surfactant vesicle based formulations using two agents; the cationic amine containing [N-(N',N'-dimethylaminoethane)-carbamoyl] cholesterol (DC-Chol) or dimethyl dioctadecylammonium bromide (DDA) with hepatitis B surface antigen (HBsAg). Synthetic mycobacterial cord factor, trehalose 6,6'-dibehenate (TDB) has been used as an adjuvant and the addition of 1-monopalmitoyl glycerol (C16:0) (MP) and cholesterol (Chol) to DDA-TDB is assessed for its potential to facilitate formation of dehydration-rehydration vesicles (DRV) at room temperature, and the effect of this on immune responses. A DRV formulation is directly compared to an adsorbed formulation of the same composition and preparation protocol (MP:dioleoyl phosphoethanolamine (DOPE):Chol:DC-Chol) and the direct substitution of MP with phosphatidylcholine (PC) is also compared in DRV antigen-entrapped formulations. MP and Chol were shown to facilitate the use of DDA-TDB in DRV formulations prepared at room temperature, whilst there was marginal alteration of immunogenicity (a reduction in HBsAg-specific IL-2). The HBsAg adsorbed DRV formulation was not significantly different from the HBsAg entrapped DRV formulation. Overall, DDA formulations incorporating TDB showed markedly increased antigen specific splenocyte proliferation and elicited cytokine production concomitant with a strong T cell driven response, delineating formulations that may be useful for further evaluation of their clinical potential.

AB - There is a clinical need for a more effective vaccine against hepatitis B, and in particular vaccines that may be suitable for therapeutic administration. This study assesses the potential of cationic surfactant vesicle based formulations using two agents; the cationic amine containing [N-(N',N'-dimethylaminoethane)-carbamoyl] cholesterol (DC-Chol) or dimethyl dioctadecylammonium bromide (DDA) with hepatitis B surface antigen (HBsAg). Synthetic mycobacterial cord factor, trehalose 6,6'-dibehenate (TDB) has been used as an adjuvant and the addition of 1-monopalmitoyl glycerol (C16:0) (MP) and cholesterol (Chol) to DDA-TDB is assessed for its potential to facilitate formation of dehydration-rehydration vesicles (DRV) at room temperature, and the effect of this on immune responses. A DRV formulation is directly compared to an adsorbed formulation of the same composition and preparation protocol (MP:dioleoyl phosphoethanolamine (DOPE):Chol:DC-Chol) and the direct substitution of MP with phosphatidylcholine (PC) is also compared in DRV antigen-entrapped formulations. MP and Chol were shown to facilitate the use of DDA-TDB in DRV formulations prepared at room temperature, whilst there was marginal alteration of immunogenicity (a reduction in HBsAg-specific IL-2). The HBsAg adsorbed DRV formulation was not significantly different from the HBsAg entrapped DRV formulation. Overall, DDA formulations incorporating TDB showed markedly increased antigen specific splenocyte proliferation and elicited cytokine production concomitant with a strong T cell driven response, delineating formulations that may be useful for further evaluation of their clinical potential.

KW - cultured cells

KW - drug delivery systems

KW - hepatitis B surface antigens

KW - liposomes

KW - mice

KW - inbred BALB C mice

KW - spleen

U2 - 10.1016/j.jconrel.2007.01.010

DO - 10.1016/j.jconrel.2007.01.010

M3 - Article

VL - 119

SP - 102

EP - 110

JO - Journal of Controlled Release

T2 - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 1

ER -